183 related articles for article (PubMed ID: 15719708)
1. Rationale for testing the cardiovascular risk for patients with COX-2 inhibitors on the basis of biomarker NT-proBNP.
Giannitsis E
Clin Lab; 2005; 51(1-2):63-83. PubMed ID: 15719708
[TBL] [Abstract][Full Text] [Related]
2. N-terminal pro-brain natriuretic peptide (NT-proBNP) in healthy blood donors and in patients from general practitioners with and without a diagnosis of cardiac disease.
Hess G; Runkel S; Zdunek D; Hitzler WE
Clin Lab; 2005; 51(3-4):167-72. PubMed ID: 15819172
[TBL] [Abstract][Full Text] [Related]
3. [Clinical utility of the cardiac markers BNP and NT-proBNP].
Buchner S; Riegger G; Luchner A
Acta Med Austriaca; 2004; 31(4):144-51. PubMed ID: 15732251
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.
Bresalier RS; Sandler RS; Quan H; Bolognese JA; Oxenius B; Horgan K; Lines C; Riddell R; Morton D; Lanas A; Konstam MA; Baron JA;
N Engl J Med; 2005 Mar; 352(11):1092-102. PubMed ID: 15713943
[TBL] [Abstract][Full Text] [Related]
5. The trade-off between cardiovascular and gastrointestinal effects of rofecoxib.
Florentinus SR; Heerdink ER; de Boer A; van Dijk L; Leufkens HG
Pharmacoepidemiol Drug Saf; 2005 Jul; 14(7):437-41. PubMed ID: 15937867
[TBL] [Abstract][Full Text] [Related]
6. COX-2 selective inhibitors cardiac toxicity: getting to the heart of the matter.
Davies NM; Jamali F
J Pharm Pharm Sci; 2004 Oct; 7(3):332-6. PubMed ID: 15576013
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of B-Type natriuretic peptides in patients with stable coronary artery disease: the PEACE Trial.
Omland T; Sabatine MS; Jablonski KA; Rice MM; Hsia J; Wergeland R; Landaas S; Rouleau JL; Domanski MJ; Hall C; Pfeffer MA; Braunwald E;
J Am Coll Cardiol; 2007 Jul; 50(3):205-14. PubMed ID: 17631211
[TBL] [Abstract][Full Text] [Related]
8. [Withdrawal of rofecoxib: a sign to be careful with coxibs in patients with increased cardiovascular risk].
Bijlsma JW
Ned Tijdschr Geneeskd; 2004 Oct; 148(44):2162-4. PubMed ID: 15559407
[TBL] [Abstract][Full Text] [Related]
9. [Selective Cox-2 inhibitor in osteoarthritis and rheumatoid arthritis. No increased risk for the heart].
MMW Fortschr Med; 2003 Mar; 145(11):60. PubMed ID: 12688204
[No Abstract] [Full Text] [Related]
10. Serial NT-proBNP monitoring and outcomes in outpatients with decompensation of heart failure.
Bayes-Genis A; Pascual-Figal D; Fabregat J; Domingo M; Planas F; Casas T; Ordoñez-Llanos J; Valdes M; Cinca J
Int J Cardiol; 2007 Sep; 120(3):338-43. PubMed ID: 17174423
[TBL] [Abstract][Full Text] [Related]
11. Can measurement of B-type natriuretic peptide levels improve cardiovascular disease prevention?
Campbell DJ
Clin Exp Pharmacol Physiol; 2008 Apr; 35(4):442-6. PubMed ID: 18307738
[TBL] [Abstract][Full Text] [Related]
12. N-terminal brain natriuretic peptide predicted cardiovascular events stronger than high-sensitivity C-reactive protein in hypertension: a LIFE substudy.
Olsen MH; Wachtell K; Nielsen OW; Hall C; Wergeland R; Ibsen H; Kjeldsen SE; Devereux RB; Dahlöf B; Hildebrandt PR
J Hypertens; 2006 Aug; 24(8):1531-9. PubMed ID: 16877955
[TBL] [Abstract][Full Text] [Related]
13. Growth differentiation factor-15 as a prognostic marker in patients with acute myocardial infarction.
Khan SQ; Ng K; Dhillon O; Kelly D; Quinn P; Squire IB; Davies JE; Ng LL
Eur Heart J; 2009 May; 30(9):1057-65. PubMed ID: 19168526
[TBL] [Abstract][Full Text] [Related]
14. Usefulness and predictive value of circulating NT-proBNP levels to stratify patients for referral and priority treatment in a specialized outpatient heart failure center.
Amir O; Paz H; Ammar R; Yaniv N; Schliamser JE; Lewis BS
Isr Med Assoc J; 2008 Feb; 10(2):109-12. PubMed ID: 18432021
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular issues of COX-2 inhibitors and NSAIDs.
Wong M; Chowienczyk P; Kirkham B
Aust Fam Physician; 2005 Nov; 34(11):945-8. PubMed ID: 16299629
[TBL] [Abstract][Full Text] [Related]
16. Can NT-proBNP predict risk of cardiovascular mortality within 10 years? Results from an epidemiological study of elderly patients with symptoms of heart failure.
Alehagen U; Dahlström U
Int J Cardiol; 2009 Apr; 133(2):233-40. PubMed ID: 18407361
[TBL] [Abstract][Full Text] [Related]
17. The relationship between N-terminal pro-brain natriuretic peptide and risk for hospitalization and mortality is curvilinear in patients with chronic heart failure.
Schou M; Gustafsson F; Corell P; Kistorp CN; Kjaer A; Hildebrandt PR
Am Heart J; 2007 Jul; 154(1):123-9. PubMed ID: 17584564
[TBL] [Abstract][Full Text] [Related]
18. Aminoterminal B-type pro-natriuretic peptide as a marker of recovery after high-risk coronary artery bypass grafting in patients with ischemic heart disease and severe impaired left ventricular function.
Rothenburger M; Stypmann J; Bruch C; Wichter T; Hoppe M; Drees G; Berendes E; Huelsken G; Loeher A; Welp H; Röttger C; Schmid C; Scheld HH; Tjan TD
J Heart Lung Transplant; 2006 May; 25(5):596-602. PubMed ID: 16678040
[TBL] [Abstract][Full Text] [Related]
19. [Is there a future for COX-2 inhibitors?].
Yodfat Y
Harefuah; 2004 Nov; 143(11):820-4, 837. PubMed ID: 15603272
[TBL] [Abstract][Full Text] [Related]
20. Glomerular filtration rate and N-terminal pro-brain natriuretic peptide as predictors of cardiovascular mortality in vascular patients.
Shadman R; Allison MA; Criqui MH
J Am Coll Cardiol; 2007 Jun; 49(22):2172-81. PubMed ID: 17543637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
